115 results about "Psoriasis arthropathy" patented technology

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis or psoriatic arthritis, utilizing anti-IL-23A antibodies.

A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant ACR20 / 50 / 70, PASI70 / 90 / 100, MDA, HAQ-DI, SF-36 PCS, MCS, LEI / dactylitis, PASDAS, GRACE, mCPDAI, DAPSA or RAPID3 improvement as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

The invention discloses a method and a system for constructing an intelligent typing diagnosis model of psoriasis. The method comprises the following steps: S1, collecting pairing multi-modal data of a psoriasis patient whose fingernails are not tired, wherein the pairing multi-modal data comprises clinical information, scanning electron microscope images of fingernail surface morphology and infrared spectrum data of fingernail protein; s2, constructing a clinical feature encoder; s3, constructing a spectral feature encoder; s4, constructing an image feature encoder; s5, constructing a hierarchical fusion module; and S6, three loss function components are constructed, multi-objective optimization of the model is realized, and a total loss function is adopted to carry out model training. According to the method, the clinical information, the scanning electron microscope image of the nail surface morphology and the infrared spectrum data of the nail protein are integrated, and the multi-mode deep learning technology is combined, so that early recognition and prediction of psoriatic arthritis in a psoriasis patient are realized.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

To provide a method for treating psoriatic arthritis.SOLUTION: Provided is a method for treating psoriatic arthritis which includes administering an anti IL-23p19 antibody hum13B8-b to a patient who needs it. Further, a method for determining effectiveness of an anti IL-23p19 antibody for treating psoriatic arthritis which includes administering an anti IL-23p19 antibody hum13B8-b to a patient is also provided.SELECTED DRAWING: None

The invention is related to methods of treatment of active psoriatic arthritis (PsA). In certain embodiments, the invention provides pharmaceutical compositions of izokibep and uses thereof for treatment of active psoriatic arthritis.

The present invention relates to compounds that are peptide inhibitors of the interleukin-23 receptor (IL-23R) and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including inflammatory diseases, such as inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), psoriasis and psoriatic arthritis. The compound has good physical and chemical stability in the gastrointestinal tract.

Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein (I) can inhibit TNFR1 and is expected to be useful as a therapeutic agent for treating, for example, inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa.The present disclosure also provides a pharmaceutical composition comprising the compound disclosed herein or a pharmaceutically acceptable salt thereof.The present disclosure also relates to a method of using the compound or a pharmaceutically acceptable salt thereof in the treatment and prevention of inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa, as well as a method of preparing a medicament for this purpose. [Formula 1] TIFF0007746628000195.tif82167

The present disclosure relates to inhibitors of miR-574-5p (SEQ ID NO: 1) for use in intra-articular treatment of a disease selected from the group consisting of osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, gout, juvenile arthritis, systemic lupus erythematosus (SLE), Sjögren's syndrome and osteoporosis.

To provide a composition comprising anti-TNF antibodies or fragments thereof for use as therapeutics for treatment of diseases mediated by TNFα, a method for treatment, and anti-TNF antibodies.SOLUTION: The present invention provides a composition for use in a treatment for patients with active Psoriatic Arthritis, the composition comprising at least one pharmaceutically acceptable carrier or diluent and at least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising a specific amino acid sequence and a light chain (LC) comprising a specific amino acid sequence.SELECTED DRAWING: None

The disclosure relates to methods of treating psoriatic arthritis in a patient comprising administering an anti-IL-23p19 antibody hum13B8-b to the patient. The disclosure also relates to pharmaceutical compositions of an anti-IL-23p19 antibody hum13B8-b for the treatment of psoriatic arthritis in a patient. The disclosure further relates to the use of an anti- IL-23p19 antibody hum13B8-b for the manufacture of a medicament for treating psoriatic arthritis in a patient. The disclosure further relates to methods, compositions, or uses wherein administration of hum13B8-b results in minimal or no serious or other side effects after up to at least about 208 weeks.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

This disclosure provides substituted 6-imidazopyridazine compounds for the modulation of IL-17A and pharmaceutical compositions thereof. These compounds are useful in the treatment of inflammatory conditions such as psoriasis, psoriatic arthritis, or ankylosing spondylitis.

The disclosure herein provides substituted 6-imidazopyridazine compounds, and pharmaceutical compositions thereof, for use in the modulation of IL-17A. These compounds are useful in the treatment of inflammatory conditions such as psoriasis, psoriatic arthritis or ankylosing spondylitis.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

The present invention belongs to the technical field of medicine, and in particular relates to a novel aromatic ring derivative containing an amide substitution or a pharmaceutically acceptable salt thereof. The diseases comprise, but are not limited to, inflammatory or autoimmune diseases such as psoriasis, psoriatic arthritis, dermatitis, lupus erythematosus, inflammatory bowel disease, hidradenitis suppurativa, rheumatoid arthritis, and uveitis. The structure of the compound of formula I is as described in the claims and the description. The aromatic ring derivative containing an amide substitution provided in the present invention is used as a novel TYK2 inhibitor, has a good TYK2 inhibitory effect, has a good therapeutic effect in an in vivo model of psoriasis and asthma animals, and has good druggability, high stability and good safety.

The present invention relates to a pharmaceutical combination comprising a first active ingredient, which is a CXCR3 antagonist 1-{(R)-2-(2-hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl}-2-(3-methyl-[1, 2, 4] triazole-5-yl)-2-(3-methyl-[1, 2, 3] triazole-5-yl)-2-(3-methyl-[1, 2, 3] triazole-5-yl)-2-(3-methyl-[1, 2, 3] a second active ingredient (which is an anti-CD3 monoclonal antibody (mAb)) and a second active ingredient (which is an anti-CD3 monoclonal antibody (mAb)); the invention also relates to the application of the medicine combination in the prevention / prevention and / or treatment of (autoimmune) / inflammation-mediated conditions (including type 1 diabetes mellitus (T1D) (especially autoimmune T1D), multiple sclerosis, organ transplant rejection (especially kidney and heart allograft rejection), thyroid eye diseases, rheumatoid arthritis, ulcerative colitis, Crohn's disease, celiac disease, and the like), and also relates to the application of the medicine combination in the prevention / prevention and / or treatment of (autoimmune) / inflammation-mediated conditions (including type 1 diabetes mellitus (T1D) (especially autoimmune T1D), multiple sclerosis, organ transplant rejection (especially kidney and heart allograft rejection), thyroid eye diseases, rheumatoid arthritis, ulcerative colitis, Crohn's disease, celiac disease and the like. The traditional Chinese medicine composition can be used for treating psoriasis, atherosclerosis, psoriasis, lung inflammation and psoriatic arthritis

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds (collectively referred to herein as CHMSA compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, hidradenitis suppurativa, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

A compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof is disclosed. The compound inhibits a toll-like receptor (TLR) signaling pathway. A composition containing the compound and uses thereof are disclosed. The novel compound blocks the TNF-α secretion by inhibiting the expression and activation of NF-κB- and MAPK-related proinflammatory genes, and thus can be utilized as a therapeutic agent for many autoimmune diseases, such as systemic lupus erythematosus, psoriasis and psoriatic arthritis, associated with a hyperactivity of a nucleic acid:

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, utilizing anti-IL-23A antibodies.

Provided herein are biomarkers and methods for generating scores useful for assessing psoriatic arthritis (PsA) disease activity in subjects previously diagnosed with PsA. The invention also provides predictive model methods based on the biomarkers, as well as computer systems, software embodiments of the models for scoring and optionally classifying samples, and methods of recommending optimal therapeutic regimens.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

The invention belongs to the technical field of medicines, and particularly relates to a novel amide-substituted aromatic ring derivative or pharmaceutically acceptable salt thereof, which comprises but is not limited to inflammatory or autoimmune diseases such as psoriasis, psoriatic arthritis, dermatitis, lupus erythematosus, inflammatory bowel disease, hidradenitis suppurativa, rheumatoid arthritis, uveitis and the like. The structure of the compound shown in the formula I is shown in the claims and the specification. As a novel TYK2 inhibitor, the amide-substituted aromatic ring derivative provided by the invention has a good TYK2 inhibition effect, has a good treatment effect in an animal in-vivo model of psoriasis and asthma, and has good druggability, high stability and good safety.

The compositions and methods provided herein are related, in part, to the discovery of cholic acid 7-sulfate as a treatment for diabetes. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVII).

The present invention relates to a method for producing an ustekinumab antibody in CHO cells. It further relates to the use of the produced antibody in the treatment of plaque psoriasis, psoriatic arthritis and inflammatory bowel disease.

To provide an etanercept pharmaceutical composition, a method for producing the same, and a method for treating a patient having rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or psoriasis.SOLUTION: A pharmaceutical composition comprising 75mM to 150mM NaCl, 5mM to 100mM arginine, 0.5% to 2% (w / v) sucrose, and 40mg to 100mg / mL etanercept, wherein the composition comprises 2. less than 0mM total additional buffer, and wherein the pH of the composition is between 6.1 and 6.5.SELECTED DRAWING: Figure 1

A pharmaceutical composition of a pyridazine derivative type inhibitor and a preparation method therefor. Specifically provided are a pharmaceutical composition, comprising a compound of formula (I) or an isomer, solvate, hydrate or pharmaceutically acceptable salt thereof or a combination thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, and a preparation method for the pharmaceutical composition. The pharmaceutical composition is used for treating psoriasis and psoriatic arthritis.